Elucidating the Prognostic Role of BRAF V600E and the Activation Status of the Downstream MAPK Pathway in PTC: A Study from a Tertiary Centre in India
<i>BRAF</i> <sup>V600E</sup>-mutated PTCs are more likely to be RAI-resistant. MAPK pathway activation status did not vary significantly with <i>BRAF</i> mutation. Immunopositivity for pMEK1/2 in most suggests a scope for MEK1-targeted therapy in recalcitrant PTC cases even in the absence of the <i>BRAF</i> mutation. In addition, IHC is a reliable technique for detecting <i>BRAF</i> <sup>V600E</sup> mutation but needs validation by correlation with molecular studies.
Authors
- Priti Chatterjee (ORCID: https://orcid.org/0000-0002-3287-9190)
- Mehar Chand Sharma (ORCID: https://orcid.org/0000-0003-4948-3296)
- Nadeem Kocheri
- Sunil Chumber (ORCID: https://orcid.org/0000-0001-6223-0571)
- Chandrasekhar Bal
- Sanjana Ballal
- Shipra Agarwal (ORCID: https://orcid.org/0000-0001-7037-4444)
Institutions
- Lady Hardinge Medical College (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- Indian Journal of Endocrinology and Metabolism
- Published
- 2024-11-01
- DOI
- https://doi.org/10.4103/ijem.ijem_235_23
- Citations
- 1
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.23